Your browser doesn't support javascript.
loading
Current practices for QSP model assessment: an IQ consortium survey.
Chan, Jason R; Allen, Richard; Boras, Britton; Cabal, Antonio; Damian, Valeriu; Gibbons, Francis D; Gulati, Abhishek; Hosseini, Iraj; Kearns, Jeffrey D; Saito, Ryuta; Cucurull-Sanchez, Lourdes; Selimkhanov, Jangir; Stein, Andrew M; Umehara, Kenichi; Wang, Guanyu; Wang, Weirong; Neves-Zaph, Susana.
Afiliación
  • Chan JR; Global PKPD and Pharmacometrics, Eli Lilly and Company, Indianapolis, IN, 46285, USA. jrchan@lilly.com.
  • Allen R; Worldwide Research, Development and Medical, Pfizer Inc. Kendall Square, Cambridge, MA, 02139, USA.
  • Boras B; Worldwide Research, Development and Medical, Pfizer Inc.,, La Jolla, CA, 92121, USA.
  • Cabal A; Eisai Inc., NJ, Nutley, USA.
  • Damian V; GlaxoSmithKline, Collegeville, PA, 19426, USA.
  • Gibbons FD; , Takeda, Cambridge, MA, 02139, USA.
  • Gulati A; Merck & Co. Inc., Rahway, NJ, USA.
  • Hosseini I; Genentech Inc., South San Francisco, CA, 94080, USA.
  • Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA.
  • Saito R; Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
  • Cucurull-Sanchez L; GlaxoSmithKline, Stevenage, Hertfordshire, UK.
  • Selimkhanov J; Takeda Development Center Americas Inc., San Diego, CA, 92121, USA.
  • Stein AM; Pharmacometrics, Novartis Institutes of BioMedical Research, Cambridge, MA, USA.
  • Umehara K; Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Wang G; Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Abingdon, Oxfordshire, UK.
  • Wang W; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, LLC, Spring House, PA, 19477, USA.
  • Neves-Zaph S; Data and Data Science, Translational Disease Modeling, Sanofi, USA.
J Pharmacokinet Pharmacodyn ; 2022 Aug 11.
Article en En | MEDLINE | ID: mdl-35953664
Quantitative Systems Pharmacology (QSP) modeling is increasingly applied in the pharmaceutical industry to influence decision making across a wide range of stages from early discovery to clinical development to post-marketing activities. Development of standards for how these models are constructed, assessed, and communicated is of active interest to the modeling community and regulators but is complicated by the wide variability in the structures and intended uses of the underlying models and the diverse expertise of QSP modelers. With this in mind, the IQ Consortium conducted a survey across the pharmaceutical/biotech industry to understand current practices for QSP modeling. This article presents the survey results and provides insights into current practices and methods used by QSP practitioners based on model type and the intended use at various stages of drug development. The survey also highlights key areas for future development including better integration with statistical methods, standardization of approaches towards virtual populations, and increased use of QSP models for late-stage clinical development and regulatory submissions.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: J Pharmacokinet Pharmacodyn Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: J Pharmacokinet Pharmacodyn Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos